Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan

登录注册会员服务联系我们

Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan–RENATEN Network

Published:2024-08-01 Issue:9 Volume:65 Page:1416-1422
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Fosse Aurelien,Hadoux Julien,Girot Paul,Beron Amandine,Afchain Pauline,Cottereau Anne-Segolene,Baudin Eric,Dierickx Lawrence O.,Lecomte Thierry,Perrier Marine,Lepage Come,Bouhier-Leporrier Karine,Goichot Bernard,Lachachi Boumediene,Walter Thomas,Durand Alice

Publisher

Society of Nuclear Medicine

Reference15 articles.

1. The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms;Borbath;Eur J Cancer.,2022

2. Everolimus for Advanced Pancreatic Neuroendocrine Tumors

3. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

4. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

5. Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP